» Articles » PMID: 35370361

CRISPR-Cas13a Cascade-based Viral RNA Assay for Detecting SARS-CoV-2 and Its Mutations in Clinical Samples

Overview
Date 2022 Apr 4
PMID 35370361
Authors
Affiliations
Soon will be listed here.
Abstract

SARS-CoV-2 is one of the greatest threats to global human health. Point-of-care diagnostic tools for SARS-CoV-2 could facilitate rapid therapeutic intervention and mitigate transmission. In this work, we report CRISPR-Cas13a cascade-based viral RNA (Cas13C) assay for label-free and isothermal determination of SARS-CoV-2 and its mutations in clinical samples. Cas13a/crRNA was utilized to directly recognize the target of SARS-CoV-2 RNA, and the recognition events sequentially initiate the transcription amplification to produce light-up RNA aptamers for output fluorescence signal. The recognition of viral RNA via Cas13a-guide RNA ensures a high specificity to distinguish SARS-CoV-2 from MERS-CoV and SARS-CoV, as well as viral mutations. A post transcription amplification strategy was triggered after CRISPR-Cas13a recognition contributes to an amplification cascade that achieves high sensitivity for detecting SARS-CoV-2 RNA, with a limit of detection of 0.216 fM. In addition, the Cas13C assay could be able to discriminate single-nucleotide mutation, which was proven with N501Y in SARS-Cov-2 variant. This method was validated by a 100% agreement with RT-qPCR results from 12 clinical throat swab specimens. The Cas13C assay has the potential to be used as a routine nucleic acid test of SARS-CoV-2 virus in resource-limited regions.

Citing Articles

Detection of Potato Pathogen by CRISPR/Cas13a Analysis of NASBA Amplicons.

Khmeleva S, Kurbatov L, Ptitsyn K, Timoshenko O, Morozova D, Suprun E Int J Mol Sci. 2024; 25(22).

PMID: 39596282 PMC: 11595182. DOI: 10.3390/ijms252212218.


Fluorogenic RNA-Based Biosensors of Small Molecules: Current Developments, Uses, and Perspectives.

Kehrli J, Husser C, Ryckelynck M Biosensors (Basel). 2024; 14(8).

PMID: 39194605 PMC: 11352751. DOI: 10.3390/bios14080376.


Evolution and Impact of Nucleic Acid Amplification Test (NAAT) for Diagnosis of Coronavirus Disease.

Khan S, Rathod P, Gupta V, Khedekar P, Chikhale R Anal Chem. 2024; 96(20):8124-8146.

PMID: 38687959 PMC: 11112543. DOI: 10.1021/acs.analchem.3c05225.


PCR Independent Strategy-Based Biosensors for RNA Detection.

Li X, Wang H, Qi X, Ji Y, Li F, Chen X Biosensors (Basel). 2024; 14(4).

PMID: 38667193 PMC: 11048163. DOI: 10.3390/bios14040200.


SARS-CoV-2 and Its Omicron Variants Detection with RT-RPA -CRISPR/Cas13a-Based Method at Room Temperature.

Li J, Wang X, Chen L, Duan L, Tan F, Li K Rep Biochem Mol Biol. 2024; 12(3):425-437.

PMID: 38618265 PMC: 11015926. DOI: 10.61186/rbmb.12.3.425.


References
1.
Zhang J, Zhang Y, Kang J, Chen S, He Y, Han B . Potential transmission chains of variant B.1.1.7 and co-mutations of SARS-CoV-2. Cell Discov. 2021; 7(1):44. PMC: 8203788. DOI: 10.1038/s41421-021-00282-1. View

2.
Luo X, Xue Y, Ju E, Tao Y, Li M, Zhou L . Digital CRISPR/Cas12b-based platform enabled absolute quantification of viral RNA. Anal Chim Acta. 2022; 1192:339336. DOI: 10.1016/j.aca.2021.339336. View

3.
Gootenberg J, Abudayyeh O, Kellner M, Joung J, Collins J, Zhang F . Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018; 360(6387):439-444. PMC: 5961727. DOI: 10.1126/science.aaq0179. View

4.
Marraffini L, Sontheimer E . CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science. 2008; 322(5909):1843-5. PMC: 2695655. DOI: 10.1126/science.1165771. View

5.
East-Seletsky A, OConnell M, Knight S, Burstein D, Cate J, Tjian R . Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature. 2016; 538(7624):270-273. PMC: 5576363. DOI: 10.1038/nature19802. View